Claritin RediTabs (10 mg loratadine rapidly-disintegrating tablet)
Company: Schering-Plough
Approval Status: Approved January 1997
Treatment for: seasonal allergy symptoms
Areas: Pulmonary/Respiratory Diseases
Possible similar drugs: Claritin Syrup
| General Information | Clinical Results |
General Information
Claritin, the first and only nondrowsy allergy product available in a ready-to-take, rapidly disintegrating tablet, has been approved for the treatment of seasonal allergy symptoms. The unique formulation of Claritian RediTabs enables the tablet to disintegrate almost instantly in the mouth, delivering the proven efficacy and safety benefits of regular nonsedating Claritin tablets.
Claritian RediTabs is indicated for the relief of seasonal allergy symptoms, including itchy, watery eyes; itchy palate; sneezing; and chronic idiopathic urticaria (commonly known as hives). Available by prescription in a once daily, nonsedating tablet, Claritian RediTabs can be administered to adults and children as young as 6 years of age, making it an especially appropriate alternative for children.
Clinical Results
In controlled clinical trials using the recommended dose, the incidence of the most commonly reported adverse events was comparable to placebo.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
